Perceptive Advisors

Agile Therapeutics is a women's healthcare company dedicated to addressing the unmet health needs of women through the development and commercialization of prescription contraceptive products. The company's lead product, Twirla, is a once-weekly transdermal patch that delivers a combination of levonorgestrel and ethinylestradiol, providing a non-daily contraceptive option. In addition to Twirla, Agile Therapeutics is advancing a pipeline of related products, including various regimens designed to offer customizable menstrual cycle management options, such as AG200-ER for extended cycles and AG200-SP for lighter periods. The firm's proprietary Skinfusion technology facilitates effective drug delivery through the skin. Headquartered in Princeton, New Jersey, Agile Therapeutics aims to enhance women's reproductive health by providing innovative contraceptive solutions.

Foamix Pharmaceuticals is a specialty pharmaceutical company based in Bridgewater, New Jersey, that focuses on the development and commercialization of proprietary topical drugs for dermatological conditions, as well as for ophthalmologic and gynecologic applications. Founded in 2014, the company utilizes its Molecule Stabilizing Technology platform to create innovative foam-based formulations. Its lead product, a first-in-class Topical Minocycline Foam, targets significant markets in dermatology and ophthalmology, having shown high efficacy and favorable safety in clinical trials for conditions such as acne and impetigo. Foamix's pipeline includes multiple drug candidates aimed at treating various skin conditions, including FMX101, FMX102, FMX103, and FDX104. The company is also engaged in development and licensing agreements with other pharmaceutical firms, enhancing its reach in the healthcare market.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company offers a range of products, including BIVIGAM and ASCENIV, both intravenous immune globulin therapies for primary humoral immunodeficiency, as well as Nabi-HB, which is used for acute exposure to Hepatitis B. ADMA is also involved in the development of additional plasma-derived therapeutics, particularly targeting infections like S. pneumonia. To support its operations, the company runs FDA-licensed source plasma collection facilities known as ADMA BioCenters, which contribute to the supply of plasma necessary for its product manufacturing. ADMA Biologics distributes its products through independent distributors, sales agents, specialty pharmacies, and other healthcare providers. Founded in 2004 and based in Ramsey, New Jersey, ADMA is dedicated to serving niche patient populations, particularly those with compromised immune systems.

Vyome Therapeutics is a biopharmaceutical company focused on developing novel drugs to combat antibiotic-resistant acne and other opportunistic pathogens. The company offers a range of products, including VB 1953, its lead molecule aimed at addressing the unmet needs in the drug-resistant acne market, as well as DARTS, which prevents resistance development in acne and other pathogens. Additionally, Vyome's portfolio includes various anti-dandruff treatments, such as VB 001, an anti-dandruff scalp care product, VB 2421, an anti-dandruff hair gel, VB 3222, a wash-off shampoo, and VB 7731, a Ketoconazole emulsion gel. Established in 2010 and headquartered in Princeton, New Jersey, Vyome Therapeutics is committed to innovation through its risk-mitigated development platform and state-of-the-art research infrastructure. The company aims to provide effective solutions for refractory skin conditions, enhancing treatment options for patients and healthcare professionals.

Vyome Therapeutics is a biopharmaceutical company focused on developing novel drugs to combat antibiotic-resistant acne and other opportunistic pathogens. The company offers a range of products, including VB 1953, its lead molecule aimed at addressing the unmet needs in the drug-resistant acne market, as well as DARTS, which prevents resistance development in acne and other pathogens. Additionally, Vyome's portfolio includes various anti-dandruff treatments, such as VB 001, an anti-dandruff scalp care product, VB 2421, an anti-dandruff hair gel, VB 3222, a wash-off shampoo, and VB 7731, a Ketoconazole emulsion gel. Established in 2010 and headquartered in Princeton, New Jersey, Vyome Therapeutics is committed to innovation through its risk-mitigated development platform and state-of-the-art research infrastructure. The company aims to provide effective solutions for refractory skin conditions, enhancing treatment options for patients and healthcare professionals.

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing innovative products that address unmet medical needs both in the United States and internationally. The company's commercial portfolio features several oral soluble film formulations, including Sympazan for Lennox-Gastaut syndrome, Suboxone for opioid dependence, Exservan for Amyotrophic Lateral Sclerosis, and Zuplenz for chemotherapy-induced nausea and vomiting. Its pipeline includes advanced candidates such as Libervant, a buccal film for epileptic seizures, and various sublingual films aimed at treating conditions like anaphylaxis and Parkinson’s disease. Founded in 2004 and headquartered in Warren, New Jersey, Aquestive Therapeutics emphasizes its commitment to addressing critical healthcare challenges, particularly in Central Nervous System disorders, while also collaborating with pharmaceutical partners to enhance its product offerings.

Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company based in Cranbury, New Jersey, specializing in the development and commercialization of monoclonal antibodies for ophthalmic conditions. The company's primary product candidate, ONS-5010, is a proprietary formulation of bevacizumab currently undergoing Phase-III clinical trials aimed at treating wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion, among other retinal diseases. Outlook Therapeutics has established collaboration and license agreements with several partners, including IPCA Laboratories Limited and Laboratorios Liomont, among others. Originally incorporated in 2010 as Oncobiologics, the company rebranded to its current name in November 2018 to better reflect its focus on ophthalmic therapeutics.

Outlook Therapeutics, Inc. is a late clinical-stage biopharmaceutical company based in Cranbury, New Jersey, specializing in the development and commercialization of monoclonal antibodies for ophthalmic conditions. The company's primary product candidate, ONS-5010, is a proprietary formulation of bevacizumab currently undergoing Phase-III clinical trials aimed at treating wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion, among other retinal diseases. Outlook Therapeutics has established collaboration and license agreements with several partners, including IPCA Laboratories Limited and Laboratorios Liomont, among others. Originally incorporated in 2010 as Oncobiologics, the company rebranded to its current name in November 2018 to better reflect its focus on ophthalmic therapeutics.

Champions Oncology, Inc. develops and sells technology solutions and products aimed at personalizing oncology drug development and treatment. Central to its offerings is the Tumorgraft Technology Platform, which involves implanting human tumors in immune-deficient mice to derive personalized treatment options based on tumor-specific data. The company provides Personalized Oncology Solutions (POS) to assist physicians in tailoring cancer therapies through drug panels and related services, as well as Translational Oncology Solutions (TOS) that help pharmaceutical and biotechnology firms in their drug development processes. Champions Oncology's products, including TumorGraft implants and drug panels, are marketed to patients and healthcare providers through various channels. Founded by leading experts in oncology, the company was established in 1985 and is headquartered in Hackensack, New Jersey.